siRNA and microRNA for the treatment of cancer

Drugs of the Future

Volumn 32, Issue 12, 2007, Pages 1061-1066

  Pento, J Thomas ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; FIBROBLAST GROWTH FACTOR; LENTIVIRUS VECTOR; MESSENGER RNA; MICRORNA; PLATELET DERIVED GROWTH FACTOR; PROTEIN P53; RETROVIRUS VECTOR; SMALL INTERFERING RNA; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR; TUMOR MARKER; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

ARTICLE; BREAST CANCER; CANCER GENE THERAPY; CANCER RESISTANCE; CHEMOPROPHYLAXIS; DNA MICROARRAY; DRUG HALF LIFE; DRUG MECHANISM; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; IMMUNOTOXICITY; LEUKEMIA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOLECULAR DYNAMICS; NONHUMAN; ONCOGENE; RETINOBLASTOMA; RNA INTERFERENCE; RNA STABILITY; STOMACH CANCER; TRANSCRIPTION REGULATION; TREATMENT INDICATION; VIRAL GENE DELIVERY SYSTEM;

EID: 41549143719     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.12.1143490     Document Type: Article

References (85)

1. Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., Mello, C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391(6669): 806-11.
2. Napoli, C., Lemieux, C., Jorgensen, R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous Ggenes in trans. Plant Cell 1990, 2(4): 279-89.
3. van der Krol, A.R., Mur, L.A., Beld, M., Mol, J.N., Stuitje, A.R. Flavonoid genes in petunia: Addition of a limited number of gene copies may lead to a suppression of gene expression. Plant Cell 1990, 2(4): 291-9.
4. Lim, L.P., Glasner, M.E., Yekta, S., Burge, C.B., Bartel, D.P. Vertebrate microRNA genes. Science 2003, 299(5612): 1540.
5. Lagos-Quintana, M., Rauhut, R., Meyer, J., Borkhardt, A., Tuschl, T. New microRNAs from mouse and human. RNA 2003, 9(2): 175-9.
6. Bartel, D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004, 116(2): 281-97.
7. Ziauddin, J., Sabatini, D.M. Microarrays of cells expressing defined cDNAs. Nature 2001, 411(6833): 107-10.
8. Tuschl, T. Functional genomics: RNA sets the standard. Nature 2003, 421(6920): 220-1.
9. Fukao, T., Fukuda, Y., Kiga, K. et al. An evolutionary conserved mechanism for microRNA-223 expression revealed by microRNA gene profiling. Cell 2007, 129(3): 617-31.
10. Pushparaj, P.N., Melendez, A.J. Short interfering RNA (siRNA) as a novel therapeutic. Clin Exp Pharmacol Physiol 2006, 33(5-6): 504-10.
11. Tuschl, T., Borkhardt, A. Small interfering RNAs: A revolutionary tool for the analysis of gene function and gene therapy. Mol Interv 2002, 2(3): 158-67.
12. Meister, G., Landthaler, M., Dorsett, Y., Tuschl, T. Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. RNA 2004, 10(3): 544-50.
13. Zimmermann, T.S., Lee, A.C., Akinc, A. et al. RNAi-mediated gene silencing in non-human primates. Nature 2006, 441(7089): 111-4.
14. Palliser, D., Chowdhury, D., Wang, Q.Y., Lee, S.J., Bronson, R.T., Knipe, D.M., Lieberman, J. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 2006, 439(7072): 89-94.
15. Song, E., Lee, S.K., Wang, J. et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003, 9(3): 347-51.
16. Sioud, M. Therapeutic potential of small interfering RNAs. Drugs Fut 2004, 29(7): 741-50.
17. Adams, A. RNAi inches toward the clinic. The Scientist 2004, 18(6): 32-5.
18. Ge, Q., Filip, L., Bai, A., Nguyen, T., Eisen, H.N., Chen, J. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci USA 2004, 101(23): 8676-81.
19. Ge, Q., McManus, M.T., Nguyen, T., Shen, C.H., Sharp, P.A., Eisen, H.N., Chen, J. RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc Natl Acad Sci USA 2003, 100(5): 2718-23.
20. Gitlin, L., Karelsky, S., Andino, R. Short interfering RNA confers intracellular antiviral immunity in human cells. Nature 2002, 418(6896): 430-4.
21. Coburn, G.A., Cullen, B.R. Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J Virol 2002, 76(18): 9225-31.
22. Lee, M.T., Coburn, G.A., McClure, M.O., Cullen, B.R. Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector. J Virol 2003, 77(22): 11964-72.
23. McCaffrey, A.P., Nakai, H., Pandey, K et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 2003, 21(6): 639-44.
24. Fuchs, U., Borkhardt, A. The application of siRNA technology to cancer biology discovery. Adv Cancer Res 2007, 96: 75-102.
25. Lucentini, J. Silencing cancer. The Scientist 2004, 18(17): 14-6.
26. Hammond, S.M. RNAi, microRNAs, and human disease. Cancer Chemother Pharmacol 2006, 58(Suppl. 1): s63-8.
27. Tonra, J.R., Hicklin, D.J. Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy. Immunol Invest 2007, 36(1): 3-23.
28. Dave, R.S. RNAi and tumor angiogenesis: Bridging the gap towards anti-cancer therapy? Leuk Res 2007, 31(4): 421-2.
29. Xu, W.H., Ge, Y.L., Li, Q., Zhang, X., Duan, J.H. Inhibitory effect of vascular endothelial growth factors-targeted small interfering RNA on proliferation of gastric cancer cells. World J Gastroenterol 2007, 13(14): 2044-7.
30. Balasubramanian, S.P., Cox, A., Cross, S.S., Higham, S.E., Brown, N.J., Reed, M.W. Influence of VEGF-A gene variation and protein levels in breast cancer susceptibility and severity. Int J Cancer 2007, 121(5): 1009-16.
31. Schneider, B.P., Sledge, G.W. Jr. Drug insight: VEGF as a therapeutic target for breast cancer. Nat Clin Pract Oncol 2007, 4: 181-9.
32. Zelnak, A.B., O'Regan, R.M. Targeting angiogenesis in advanced breast cancer. BioDrugs 2007, 21(4): 209-14.
33. Zhang, X., Xu, W.H., Ge Y.L., Hou, L., Li, Q. [Effect of siRNA transfection targeting VEGF gene on proliferation and apoptosis of human breast cancer cells]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2007, 23(1): 14-7.
34. Chen, X., Lin, J., Kanekura, T., Su, J. et al. A small interfering CD147-targeting RNA inhibited the proliferation, invasiveness, and metastatic activity of malignant melanoma. Cancer Res 2006, 66(23): 11323-30.
35. Jia, R.B., Zhang, P., Zhou, Y.X. et al. VEGF-targeted RNA interference suppresses angiogenesis and tumor growth of retinoblastoma. Ophthalmic Res 2007, 39(2): 108-15.
36. Shen, H.L., Xu, W., Wu, Z.Y., Zhou, L.L., Qin, R.J., Tang, H.R. Vector-based RNAi approach to isoform-specific downregulation of vascular endothelial growth factor (VEGF)165 expression in human leukemia cells. Leuk Res 2007, 31(4): 515-21.
37. Kim, S.E., Choi, K.Y. EGF receptor is involved in WNT3a-mediated proliferation and motility of NIH3T3 cells via ERK pathway activation. Cell Signal 2007, 19(7): 1554-64.
38. Niu, J., Xu, Z., Li, X.N., Han, Z. siRNA-mediated type 1 insulin-like growth factor receptor silencing induces chemosensitization of a human liver cancer cell line with mutant P53. Cell Biol Int 2007, 31(2): 156-64.
39. Zins, K., Abraham, D., Sioud, M., Aharinejad, S. Colon cancer cell-derived tumor necrosis factor-alpha mediates the tumor growth-promoting response in macrophages by up-regulating the colony-stimulating factor-1 pathway. Cancer Res 2007, 67(3): 1038-45.
40. Hatake, K., Tokudome, N,. Ito, Y. Next generation molecular targeted agents for breast cancer: Focus on EGFR and VEGFR pathways. Breast Cancer 2007, 14(2): 132-49.
41. Kawasaki, H., Taira, K. Induction of DNA methylation and gene silencing by short interfering RNAs in human cells. Nature 2004, 431(7005): 211-7.
42. Rejiba, S., Wack, S., Aprahamian, M., Hajri, A. K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment. Cancer Sci 2007, 98(7): 1128-36.
43. Garzon, R., Pichiorri, F., Palumbo, T. et al. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocyte leukemia. Oncogene 2007, 26(28): 4148-57.
44. Morgan-Lappe, S.E., Tucker, L.A., Huang, X. et al. Identification of Ras-related nuclear protein, targeting protein for Xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen. Cancer Res 2007, 67(9): 4390-8.
45. Bullock, A.N., Fersht, A.R. Rescuing the function of mutant p53. Nat Rev Cancer 2001, 1(1): 68-76.
46. Westbrook, T.F., Martin, E.S., Schlabach, M.R. et al. A genetic screen for candidate tumor suppressors identifies REST. Cell 2005, 121(6): 837-48.
47. Kolfschoten, I.G., van Leeuwen, B., Berns, K. et al. A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell 2005, 121(6): 849-58.
48. de Klein, A., van Kessel, A.G., Grosveld, G. et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982, 300(5894): 765-7.
49. Heisterkamp, N., Stam, K., Groffen, J., de Klein, A., Grosveld, G. Structural organization of the bcr gene and its role in the Ph' translocation. Nature 1985, 315(6022): 758-61.
50. Chaturvedi, A., Battmer, K., Schaefer, D., Ganser, A., Eder, M., Scherr, M. Comparison between molecularly defined and conventional therapeutics in a conditional BCR-ABL cell culture model. Oligonucleotides 2007, 17(1): 22-34.
51. Wilda, M., Fuchs, U., Wossmann, W., Borkhardt, A. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene 2002, 21(37): 5716-24.
52. Baker, B.E., Kestler, D.P., Ichiki, A.T. Effects of siRNAs in combination with Gleevec on K-562 cell proliferation and Bcr-Abl expression. J Biomed Sci 2006, 13(4): 499-507.
53. Sengupta, A., Banerjee, D., Chandra, S., Banerjee, S. Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector. J Gene Med 2006, 8(10): 1251-61.
54. Hammond, S.M. MicroRNA therapeutics: A new niche for antisense nucleic acids. Trends Mol Med 2006, 12(3): 99-101.
55. Croce, C.M., Calin, G.A. miRNAs, cancer, and stem cell division. Cell 2005, 122(1): 6-7.
56. Hammond, S.M. MicroRNAs as oncogenes. Curr Opin Genet Dev 2006, 16(1): 4-9.
57. O'Donnell, K.A., Wentzel, E.A., Zeller, K.I., Dang, C.V., Mendell, J.T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435(7043): 839-43.
58. He, L., Thomson, J.M., Hemann, M.T. et al. A microRNA polycistron as a potential human oncogene. Nature 2005, 435(7043): 828-33.
59. Michael, M.Z., O'Connor, S.M., van Holst Pellekaan, N.G., Young, G.P., James, R.J. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003, 1(12): 882-91.
60. Takamizawa, J., Konishi, H., Yanagisawa, K. et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004, 64(11): 3753-6.
61. Iorio, M.V., Ferracin, M., Liu, C.G. et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005, 65(16): 7065-70.
62. He, H., Jazdzewski, K., Li, W. et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 2005, 102(52): 19075-80.
63. Lee, E.J., Gusev, Y., Jiang, J. et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007, 120(5): 1046-54.
64. Chan, J.A., Krichevsky, A.M., Kosik, K.S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005, 65(14): 6029-33.
65. Calin, G.A., Liu, C.G., Sevignani, C. et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 2004, 101(32): 11755-60.
66. Calin, G.A., Sevignani, C., Dumitru, C.D. et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004, 101(9): 2999-3004.
67. Eis, P.S., Tam, W., Sun, L. et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA 2005, 102(10): 3627-32.
68. Soutschek, J., Akinc, A., Bramlage, B. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432(7014): 173-8.
69. Song, E., Zhu, P., Lee, S.K. et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-suriace receptors. Nat Biotechnol 2005, 23(6): 709-17.
70. Breckpot, K., Aerts, J.L., Thielemans, K. Lentiviral vectors for cancer immunotherapy: Transforming infectious particles into therapeutics. Gene Ther 2007, 14(11): 847-62.
71. Jounaidi, Y., Doloff, J.C., Waxman, D.J. Conditionally replicating adenoviruses for cancer treatment. Curr Cancer Drug Targets 2007, 7(3): 285-301.
72. Kwon, I., Schaffer, D.V. Designer gene delivery vectors: Molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer. Pharm Res 2007, In press.
73. Ter Brake, O., Berkhout, B. Lentiviral vectors that carry anti-HIV shRNAs: Problems and solutions. J Gene Med 2007, 9(9): 743-50.
74. Witlox, M.A., Lamfers, M.L., Wuisman, P.I., Curiel, D.T., Siegal, G.P. Evolving gene therapy approaches for osteosarcoma using viral vectors: Review. Bone 2007, 40(4): 797-812.
75. Xia, H., Mao, Q., Paulson, H.L., Davidson, B.L. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002, 20(10): 1006-10.
76. Tiscornia, G., Singer, O., Ikawa, M., Verma, I.M. A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc Natl Acad Sci USA 2003, 100(4): 1844-8.
77. Tiscornia, G., Tergaonkar, V., Galimi, F., Verma, I.M. CRE recombinase-inducible RNA interference mediated by lentiviral vectors. Proc Natl Acad Sci USA 2004, 101(19): 7347-51.
78. Dykxhoorn, D.M., Lieberman, J. Knocking down disease with siRNAs. Cell 2006, 126(2): 231-5.
79. Sledz, C.A., Holko, M., de Veer, M.J., Silverman, R.H., Williams, B.R. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003, 5(9): 834-9.
80. Bridge, A.J., Pebernard, S., Ducraux, A., Nicoulaz, A.L., Iggo, R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 2003, 34(3): 263-4.
81. Kim, D.H., Longo, M., Han, Y., Lundberg, P., Cantin, E., Rossi, J.J. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol 2004, 22(3): 321-5.
82. Reynolds, A., Leake, D., Boese, Q., Scaringe, S., Marshall, W.S., Khvorova, A. Rational siRNA design for RNA interference. Nat Biotechnol 2004, 22(3): 326-30.
83. Wu, H.I., Brown, J.A., Dorie, M.J., Lazzeroni, L., Brown, J.M. Genome-wide identification of genes conferring resistance to the anticancer agents cisplatin, oxaliplatin, and mitomycin C. Cancer Res 2004, 64(11): 3940-8.
84. Yague, E., Higgins, C.F., Raguz, S. Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1. Gene Ther 2004, 11(14): 1170-4.
85. Wu, H., Hait, W.N., Yang, J.M. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res 2003, 63(7): 1515-9.